Page 1

Alterity THERAPEUTICS Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update Highlights . FDA End - of - Phase 2 ( EOP2 ) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy ( MSA ) • FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA • Pivotal Phase 3 trial activities on track to initiate by year - end 2026 • • Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long - term shareholder value Peer - reviewed publication in Neurolmage validated quantitative susceptibility mapping ( QSM ) of iron on MRI as a biomarker of MSA Strengthened the Board of Directors with the appointment of Ms Ann Cunningham • A $ 3.98 million Australian R & D Tax Incentive refund received subsequent to quarter end , supporting continued development of Alterity's clinical programs • Cash balance of A $ 37.3 million as at 30 June 2026 - MELBOURNE , AUSTRALIA AND SAN FRANCISCO , USA – 30 July 2026 : Alterity Therapeutics ( ASX : ATH , NASDAQ : ATHE ) ( " Alterity " or " the Company " ) , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases , today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2026 ( Q4 FY26 ) . " This was a defining quarter for Alterity , highlighted by our positive End of Phase 2 meeting with the FDA that established a clear , efficient registrational pathway for ATH434 , " said David Stamler , M.D. , Chief Executive Officer . " With the Phase 3 design elements agreed upon , we are executing on our plans to initiate Phase 3 trial activities by year - end 2026. " Dr. Stamler continued , “ The regulatory clarity we have now achieved , together with the growing body of clinical evidence supporting ATH434 , puts us in a strong position as we prepare to initiate Phase 3 and continue strategic and other funding discussions aimed at maximising the long - term value of the program . "